slides · global inventory
Quote
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 18,554
Current window 15,571-15,600
Pages 619
Rows per page 30
Component
15,571-15,600 of 18,554
298
The slide uses a Q&A format to highlight the investigator's lack of enthusiasm and low patient uptake.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
299
The slide uses direct Q&A transcripts to highlight the investigator's negative sentiment and concerns about patient safety (diabetes/hyperglycemia).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
301
The slide uses a Q&A format to highlight specific allegations of misconduct regarding clinical trial reporting.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
302
The slide uses a Q&A format to highlight potential misconduct by the company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
303
The slide uses a Q&A format to highlight alleged unethical behavior by Soleno regarding academic integrity and investigator relations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
304
The slide uses a 'villain_critique' structure to undermine a competitor's clinical trial results by citing an expert's negative testimony.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
308
The slide uses direct quotes from a trial investigator to undermine the validity of clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
309
The slide uses a Q&A format to frame the investigator's critique of the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
310
The slide uses bolding and highlighting to emphasize negative feedback from a key opinion leader.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
314
The slide uses a Q&A format to highlight expert opinion against the subject drug (DCCR/Vykat).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
315
Includes verbatim Q&A transcripts highlighting the investigator's passive approach to patient recruitment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
316
The slide uses Q&A transcripts to undermine the perceived market success of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
317
The slide uses direct quotes from a trial investigator to undermine the drug's clinical value and commercial prospects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
318
The slide uses a 'quote-as-evidence' structure to undermine the clinical efficacy of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
319
The slide uses a Q&A transcript format to expose flaws in clinical trial integrity.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
320
The slide uses a Q&A format to present expert testimony from a trial investigator.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
321
The slide uses a Q&A transcript format to expose flaws in the clinical trial design regarding pill size.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
322
The slide uses a Q&A transcript format to undermine the company's product value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
323
The slide uses a combination of summary text and direct interview transcripts to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
324
The slide uses a Q&A format to highlight the failure of the trial's blinding protocol.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
326
The slide uses Q&A transcripts to expose the risks of the drug and the burden of monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
331
The slide uses direct quotes from an endocrinologist/KOL to undermine the clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
334
The slide uses direct quotes from a trial investigator to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
336
The slide uses a Q&A format to highlight the investigator's reluctance and admission of clinical risks.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
340
The slide presents a transcript of an expert consultation call to undermine the market potential of Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
345
The slide uses expert quotes to undermine the company's claims regarding the drug's safety profile and market potential.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
348
The slide presents interview transcripts highlighting a lack of buzz at a major industry conference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
349
The slide uses direct quotes to undermine the market potential and safety profile of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
351
The slide uses direct quotes to highlight physician skepticism and lack of awareness regarding the drug's trial flaws.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
352
The slide uses direct quotes to highlight the expert's negative sentiment toward the drug and the clinical trial methodology.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit